Last Updated: September 24, 2026

Wyeth Pharms Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for WYETH PHARMS

WYETH PHARMS has thirty-one approved drugs.

There are two US patents protecting WYETH PHARMS drugs.

Summary for Wyeth Pharms

US Patents:	2
Tradenames:	29
Ingredients:	18
NDAs:	31

Drugs and US Patents for Wyeth Pharms

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	ORUVAIL	ketoprofen	CAPSULE, EXTENDED RELEASE;ORAL	019816-003	Feb 8, 1995		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms	PROTONIX	pantoprazole sodium	TABLET, DELAYED RELEASE;ORAL	020987-001	Feb 2, 2000	AB	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	EFFEXOR	venlafaxine hydrochloride	TABLET;ORAL	020151-004	Dec 28, 1993		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	LODINE XL	etodolac	TABLET, EXTENDED RELEASE;ORAL	020584-002	Oct 25, 1996		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	CORDARONE	amiodarone hydrochloride	INJECTABLE;INJECTION	020377-001	Aug 3, 1995		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Wyeth Pharms Inc	EFFEXOR	venlafaxine hydrochloride	TABLET;ORAL	020151-006	Dec 28, 1993		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Wyeth Pharms

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms Inc	NORPLANT SYSTEM IN PLASTIC CONTAINER	levonorgestrel	IMPLANT;IMPLANTATION	020088-001	Dec 10, 1990	3,850,911	⤷ Start Trial
Wyeth Pharms Inc	LODINE	etodolac	CAPSULE;ORAL	018922-003	Jan 31, 1991	4,076,831	⤷ Start Trial
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	5,547,948	⤷ Start Trial
Wyeth Pharms	PREMPHASE 14/14	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020527-002	Nov 17, 1995	RE36247	⤷ Start Trial
Wyeth Pharms	TRIPHASIL-21	ethinyl estradiol; levonorgestrel	TABLET;ORAL-21	019192-001	Nov 1, 1984	3,850,911	⤷ Start Trial
Wyeth Pharms Inc	PREMPRO (PREMARIN;CYCRIN)	estrogens, conjugated; medroxyprogesterone acetate	TABLET;ORAL-28	020303-001	Dec 30, 1994	RE36247	⤷ Start Trial
Wyeth Pharms Inc	TRIPHASIL-28	ethinyl estradiol; levonorgestrel	TABLET;ORAL-28	019190-001	Nov 1, 1984	3,957,982	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for WYETH PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	12 g/1.5 g per vial (pharmacy bulk)	➤ Subscribe	2011-12-06
➤ Subscribe	Tablets	0.09 mg/0.02 mg	➤ Subscribe	2007-10-05
➤ Subscribe	Delayed-release Tablets	20 mg and 40 mg	➤ Subscribe	2004-02-02
➤ Subscribe	Tablets	25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg	➤ Subscribe	2005-11-03

International Patents for Wyeth Pharms Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Taiwan	200524643	⤷ Start Trial
Colombia	5690538	⤷ Start Trial
Taiwan	200606149	⤷ Start Trial
Norway	20065052	⤷ Start Trial
Serbia	20060238	⤷ Start Trial
Australia	2005233133	⤷ Start Trial
Singapore	151331	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Wyeth Pharms Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	C 2015 029	Romania	⤷ Start Trial	PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
1380301	CA 2009 00017	Denmark	⤷ Start Trial	PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
1453521	15C0050	France	⤷ Start Trial	PRODUCT NAME: ETHINYLESTRADIOL ET MELANGE DE LEVONORGESTREL ET ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: NL 42237 20150320; FIRST REGISTRATION: SK - 17/0017/15-S 20150129
1539166	2013C/064	Belgium	⤷ Start Trial	PRODUCT NAME: DEXTROMETHORPHANE OU UN SEL, PRCURSEUR DE DERIVE PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRURE DE DEXTROMETORPHANE ET EN PARTICULIER LE BROMHYDRURE DE DEXTROMETROPHANE MONHYDRATE ET QUINIDINE OU UN SEL,....; AUTHORISATION NUMBER AND DATE: EU/1/13/833 20130626
1453521	132016000025143	Italy	⤷ Start Trial	PRODUCT NAME: LEVONORGESTREL ED ETINILESTRADIOLO(SEASONIQUE); AUTHORISATION NUMBER(S) AND DATE(S): 17/0017/15-S, 20150211;042139016, 20150414
0503785	CA 2011 00026	Denmark	⤷ Start Trial	PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0565634	06C0030	France	⤷ Start Trial	PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.